Product
Lenvatinib + Pembrolizumab plus SBRT combinations
1 clinical trial
3 indications
Indication
Hepatocellular CarcinomaIndication
LenvatinibIndication
Stereotactic Body RadiotherapyClinical trial
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis.Status: Not yet recruiting, Estimated PCD: 2026-09-30